Tags

Type your tag names separated by a space and hit enter

Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women.
Fertil Steril. 2004 Mar; 81(3):617-23.FS

Abstract

OBJECTIVE

To compare changes in mammographic density and the expression of markers of proliferation (Ki67) and apoptosis (Bcl-2) after 1 year of treatment with tibolone and continuous conjugated equine estrogens combined with medroxyprogesterone acetate (CEE-MPA).

DESIGN

Comparative, randomized, evaluator-blinded study.

SETTING

City research hospital.

PATIENT(S)

Thirty-seven postmenopausal women.

INTERVENTION(S)

Tibolone (2.5 mg; n = 18) or continuous conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (5 mg; n = 19) for 1 year.

MAIN OUTCOME MEASURE(S)

Mammographic density (BI-RADS density score), expression of immunohistochemical markers Ki67 and Bcl-2.

RESULT(S)

Mean breast density score decreased significantly from 2.22 to 1.67 in the tibolone group, compared with a significant increase in the CEE-MPA-treated group from 1.84 to 2.63. Ki67 expression decreased in 12 of 15, increased in 2 of 15, and remained unchanged in 1 of 15 subjects in the tibolone group, compared with 1 of 19, 15 of 19, and 3 of 19 subjects, respectively, in the CEE-MPA group. Bcl-2 expression decreased in 12 of 15, increased in 2 of 15, and remained unchanged in 1 of 15 subjects in the tibolone group, compared with 5 of 19, 9 of 19, and 5 of 19 subjects, respectively, in the CEE-MPA group.

CONCLUSION(S)

One-year treatment with tibolone induced a decrease in breast density, with a reduction in proliferation and a stimulation of apoptosis, whereas 1-year treatment with CEE-MPA induced an increase in breast density, with stimulation of proliferation and inhibition of apoptosis, indicating that tibolone effects on the breast are different from those of CEE-MPA.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, University of Chile, Santiago, Chile. imvaldivia@entelchile.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15037411

Citation

Valdivia, Isabel, et al. "Effects of Tibolone and Continuous Combined Hormone Therapy On Mammographic Breast Density and Breast Histochemical Markers in Postmenopausal Women." Fertility and Sterility, vol. 81, no. 3, 2004, pp. 617-23.
Valdivia I, Campodónico I, Tapia A, et al. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril. 2004;81(3):617-23.
Valdivia, I., Campodónico, I., Tapia, A., Capetillo, M., Espinoza, A., & Lavín, P. (2004). Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertility and Sterility, 81(3), 617-23.
Valdivia I, et al. Effects of Tibolone and Continuous Combined Hormone Therapy On Mammographic Breast Density and Breast Histochemical Markers in Postmenopausal Women. Fertil Steril. 2004;81(3):617-23. PubMed PMID: 15037411.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. AU - Valdivia,Isabel, AU - Campodónico,Italo, AU - Tapia,Augusto, AU - Capetillo,María, AU - Espinoza,Arturo, AU - Lavín,Pablo, PY - 2003/01/21/received PY - 2003/07/31/revised PY - 2003/07/31/accepted PY - 2004/3/24/pubmed PY - 2004/4/29/medline PY - 2004/3/24/entrez SP - 617 EP - 23 JF - Fertility and sterility JO - Fertil. Steril. VL - 81 IS - 3 N2 - OBJECTIVE: To compare changes in mammographic density and the expression of markers of proliferation (Ki67) and apoptosis (Bcl-2) after 1 year of treatment with tibolone and continuous conjugated equine estrogens combined with medroxyprogesterone acetate (CEE-MPA). DESIGN: Comparative, randomized, evaluator-blinded study. SETTING: City research hospital. PATIENT(S): Thirty-seven postmenopausal women. INTERVENTION(S): Tibolone (2.5 mg; n = 18) or continuous conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (5 mg; n = 19) for 1 year. MAIN OUTCOME MEASURE(S): Mammographic density (BI-RADS density score), expression of immunohistochemical markers Ki67 and Bcl-2. RESULT(S): Mean breast density score decreased significantly from 2.22 to 1.67 in the tibolone group, compared with a significant increase in the CEE-MPA-treated group from 1.84 to 2.63. Ki67 expression decreased in 12 of 15, increased in 2 of 15, and remained unchanged in 1 of 15 subjects in the tibolone group, compared with 1 of 19, 15 of 19, and 3 of 19 subjects, respectively, in the CEE-MPA group. Bcl-2 expression decreased in 12 of 15, increased in 2 of 15, and remained unchanged in 1 of 15 subjects in the tibolone group, compared with 5 of 19, 9 of 19, and 5 of 19 subjects, respectively, in the CEE-MPA group. CONCLUSION(S): One-year treatment with tibolone induced a decrease in breast density, with a reduction in proliferation and a stimulation of apoptosis, whereas 1-year treatment with CEE-MPA induced an increase in breast density, with stimulation of proliferation and inhibition of apoptosis, indicating that tibolone effects on the breast are different from those of CEE-MPA. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/15037411/Effects_of_tibolone_and_continuous_combined_hormone_therapy_on_mammographic_breast_density_and_breast_histochemical_markers_in_postmenopausal_women_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015028203030498 DB - PRIME DP - Unbound Medicine ER -